With developing technologies, treatments for ailments are also experiencing a monumental reach. The trial of EMBRaNCE has come up with innovative ideas for treating cancer and tending to patients' needs when required.
FREMONT, CA: A recent trial in Great Manchester explicated wearable technologies for patients undergoing cancer treatments. A digital fingerprint of vital signs is produced by accessible health sensors and devices. This trial is a collaboration between Manchester University NHS Foundation Trust, The Christie NHS Foundation Trust and The University of Manchester and is labelled as EMBRaNCE (Enhanced Monitoring for Better Recovery and Cancer Experience). Initially, the trial was open for blood, lung, and colorectal cancer patients with a plan to expand it all across Great Manchester.
Technologies Under Investigation
A smart ring that can be worn on any finger.
A continuous remote monitoring system for patients that can be worn on the chest.
This developed technology can monitor a range of vital signs that include electrocardiogram (ECG), heart rate, temperature, physical activity levels and sleep. This clinical project is led by Dr Anthony Wilson, a Consultant in Anesthesia and Critical Care at MRI (Manchester Royal Infirmary). According to him, cancer is a chronic ailment that affects people globally. With advanced technologies and accessible devices, the study helps in monitoring people and their coping mechanisms. With this information, recovery methods can be planned accordingly.
A senior lecturer in Proton Therapy Physics, Dr Michael Merchant, stated that the trial would provide methods for analyzing technology’s role in cancer cure. If the monitored data supports the cure, digital platforms can be developed involving fitness devices and health trackers. The first trial is planned to be carried out on a 70-year-old lymphoma patient. Due to his current medications, his trial is scheduled to post a couple of weeks after his first infusion of CAR-T (Chimeric Antigen Receptor T-cell) therapy. When asked about his consent, the patient replied that he is elated to help with the technology as he assumes the idea to be remarkable.
GM Cancer Digital Innovation Fund, UK Research and Innovation and the National Institute of Health Research (NIHR), along with a few other companies, have funded EMBRaNCE. The CEOs of the funding companies have expressed their satisfaction with how their creation to support COVID-19 research has undergone a modification and is being used as wearables to support cancer patients’ cures. The trial has joined hands with a health and biomedical data science company to harness the power of artificial intelligence (AI) that helps in analyzing the key patterns within patient data. The company’s CEO expressed his belief in the future of healthcare for improving patient outcomes on an individual basis. Sharing his excitement over the collaboration, he elucidated the use of technology, knowledge, and expertise in wearable devices enabled by AI. It could make a potential difference in the lives of patients.
A cancer survivor shared the frightening experiences that a cancer patient goes through, excluding the clinical treatments. It includes anxiety, fatigue, and disturbed sleep. Psychological support is one of the predominant needs of cancer patients. Hence, this clinical trial aims at taking proactive measures to control cancer.
The Great Manchester Cancer Alliance’s director has put up a statement that the smart use of digital technology has crucial importance in providing personalized care for cancer patients. As he is exhilarated over the trial happening at Great Manchester, the expectations for a positive outcome of the trial are highly anticipated.
Thus, the emergence of EMBRaNCE has fostered hope among cancer patients over their successful recovery with regular monitoring of their health.